The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search feed instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content



The United States Food and Drug Administration announced last fall that they had confirmed the presence of NDMA,  a potential cancer-causing chemical, in Zantac and its generic counterpart, ranitidine.

Since the FDA announcement hundreds of lawsuits have been filed against drug makers. Sanofi-Aventis U.S., which recalled over-the-counter Zantac on October 18, 2019, is one of several defendants named in the cases. Other defendants include GlaxoSmithKline, which first received FDA approval to sell the drug and recalled prescription Zantac on Oct. 8, and Boehringer Ingelheim Pharmaceuticals Inc. and Pfizer Inc., which both sold Zantac.

The growing number of cases has led to a consolidation known as a multidistrict litigation, or MDL, which is a management procedure used to streamline pretrial and discovery processes. On February 6, 2020 federal judges approved the transfer of 15 Zantac-related lawsuits to the Southern District of Florida, where U.S. District Judge Robin Rosenberg will preside over them. According to the transfer order, another 126 cases are pending in 21 districts nationwide. One of those cases was filed by Saunders and Walker P.A.

This action allows potentially thousands of additional Zantac-related lawsuits to also join the litigation. At Saunders & Walker we predict a large increase in the number of cases over Zantac, which has been on the market since 1983.

The research is still in its early stages, but all indications so far show that many ranitidine medicines – including Zantac contain potentially dangerous levels of the cancer-causing drug nitrosodimethylamine (NDMA). If you have taken Zantac and had a diagnosis of a primary cancer of the digestive tract, such as small intestine, colorectal, esophageal, liver, bladder, and pancreatic cancers, or if you have a blood related cancer such as leukemia, non-Hodgkin’s lymphoma, or multiple myeloma – it might possibly be related to Zantac use and you should seek legal advice.

At Saunders & Walker we urge that if you are taking Zantac or a generic equivalent to please consult your physician or pharmacist and find out if you need a replacement. If you or a loved one took Zantac or a generic equivalent and have been diagnosed with cancer, please contact Saunders & Walker at 1-800-748-7115 for a free consultation and learn more about case eligibility and whether you may be entitled to financial compensation.


One Comment

  1. Gravatar for jose monserrate
    jose monserrate

    My mother Elizabeth Monserrate 11/21/1944 was a constant user of over the counter Zantac for more than 19 yrs. On June 12, 2017 my mother was hospitalized for terminal gald bladder, lung & liver Cancer. She passed on July 07, 2017. Before this diagnosis my mother was in great health she had osteoarthritis which she had therapy for & had hypertension however she was never diagnosed with any other abnormalities. All her medical records are at Bellevue Hospital in NYC.

Comments for this article are closed, but you may still contact the author privately.